Discovery of a selective inhibitor of doublecortin like kinase 1

Journal: Nature Chemical Biology

Published: 2020-04-06

DOI: 10.1038/s41589-020-0506-0

Affiliations: 24

Authors: 37

Go to article
Institutions Share
Broad Institute of MIT and Harvard, United States of America (USA) 0.11
Promega Corporation, United States of America (USA) 0.11
Department of Cancer Biology, DFCI, United States of America (USA) 0.08
Department of Medical Oncology, DFCI, United States of America (USA) 0.08
Therapeutic Innovation Center (THINC), United States of America (USA) 0.05
Harvard Department of Biological Chemistry and Molecular Pharmacology (BCMP), United States of America (USA) 0.05
Department of Radiation Oncology, DFCI, United States of America (USA) 0.05
Cancer Research Institute, BIDMC, United States of America (USA) 0.04
Department of Medicine, BIDMC, United States of America (USA) 0.04
Department of Biochemistry and Molecular Biology, UAB, Spain 0.04
Institut de Neurociències (INc), UAB, Spain 0.04
Department of Pediatric Oncology, DFCI, United States of America (USA) 0.04
Department of Radiation Oncology, UT Southwestern Medical Center, United States of America (USA) 0.04
Department of Biochemistry, UT Southwestern Medical Center, United States of America (USA) 0.04
Department of Cell and Developmental Biology (CDB), U-M, United States of America (USA) 0.03
KU-KIST Graduate School of Converging Science and Technology, South Korea 0.03
NDBio Therapeutics Inc., South Korea 0.03
Department of Medicine (DOM), BWH, United States of America (USA) 0.02
Harvard Medical School (HMS), United States of America (USA) 0.02
Department of Pediatrics (DoP), BCH, United States of America (USA) 0.01
Global Vaccines R&D Centre Rockville, United States of America (USA) 0.01
Harvard Digestive Diseases Center (HDDC), United States of America (USA) 0.01
Harvard Department of Medicine, United States of America (USA) 0.01
Harvard Department of Pathology, United States of America (USA) 0.01

Return